Showing results (1921-1930 of 9,980) with videos related to
Sort By:
Pageof 998
Leukemia & Lymphoma|October 6, 2023
Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyondCaitlin Gribbin, Jane Chen, Peter Martin, et al.Leukemia & Lymphoma|October 5, 2023
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reportsVictor M Rivera-Francia, Virgilio E Failoc-Rojas, Robert Villacorta-Carranza, et al.Leukemia & Lymphoma|September 23, 2023
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphomaAndrew Ip, Alessandra Petrillo, Alexandra Della Pia, et al.Leukemia & Lymphoma|July 15, 2023
Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European centerMiguel Arguello-Tomas, Nil Albiol, Paola Jara, et al.Leukemia & Lymphoma|July 3, 2023
CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literatureVincenzo Guastafierro, Marta Ubezio, Nicla Manes, et al.Leukemia & Lymphoma|January 8, 2019
Ixazomib - the first oral proteasome inhibitorJingmei Xie, Ning Wan, Zhuoru Liang, et al.Leukemia & Lymphoma|January 9, 2019
Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical settingYanling Ren, Huifang Jiang, Fangjing Shi, et al.Leukemia & Lymphoma|December 4, 2018
Leukemia and male infertility: past, present, and futureYulia Michailov, Eitan Lunenfeld, Joseph Kapelushnik, et al.Leukemia & Lymphoma|February 5, 2019
PET-derived tumor metrics predict DLBCL response and progression-free survivalPrioty Islam, Jordan Goldstein, Christopher R FlowersLeukemia & Lymphoma|February 5, 2019
Monozygotic twins with shared de novo GATA2 mutation but dissimilar phenotypes due to differential promoter methylationNamhee Kim, Seongmin Choi, Sung-Min Kim, et al.Pageof 998